160 related articles for article (PubMed ID: 19580952)
1. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
Kendall DM; Cuddihy RM; Bergenstal RM
Eur J Intern Med; 2009 Jul; 20 Suppl 2():S329-39. PubMed ID: 19580952
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
Kendall DM; Cuddihy RM; Bergenstal RM
Am J Med; 2009 Jun; 122(6 Suppl):S37-50. PubMed ID: 19464427
[TBL] [Abstract][Full Text] [Related]
3. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
Barnett AH
Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
[TBL] [Abstract][Full Text] [Related]
4. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.
Bonora E
Int J Clin Pract Suppl; 2007 Aug; (154):19-28. PubMed ID: 17593274
[TBL] [Abstract][Full Text] [Related]
6. Defining the role of incretin mimetic therapy in the management of type 2 diabetes.
Unger J; Nadeau DA
J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341
[TBL] [Abstract][Full Text] [Related]
7. Incretin-based therapies in type 2 diabetes: a review of clinical results.
Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
[TBL] [Abstract][Full Text] [Related]
8. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
Zarowitz BJ; Conner C
Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
[TBL] [Abstract][Full Text] [Related]
9. Targeting the incretin system in type 2 diabetes mellitus.
Potenza M; Rayfield EJ
Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
[TBL] [Abstract][Full Text] [Related]
10. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
Mathieu C; Bollaerts K
Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
[TBL] [Abstract][Full Text] [Related]
11. Incretin based therapies for type 2 diabetes mellitus.
Ghosh S; Collier A; Elhadd T; Malik I
J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
[TBL] [Abstract][Full Text] [Related]
12. Beyond insulin replacement: addressing the additional needs of the diabetes patient.
Dailey G
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():83-97. PubMed ID: 18577160
[TBL] [Abstract][Full Text] [Related]
13. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.
Niswender K
Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648
[TBL] [Abstract][Full Text] [Related]
14. Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies.
Fonseca VA; Zinman B; Nauck MA; Goldfine AB; Plutzky J
Am J Med; 2010 Jul; 123(7):S2-S10. PubMed ID: 20609666
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
Gilbert MP; Pratley RE
Eur J Intern Med; 2009 Jul; 20 Suppl 2():S309-18. PubMed ID: 19580950
[TBL] [Abstract][Full Text] [Related]
16. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
Garber AJ
J Am Osteopath Assoc; 2011 Jul; 111(7 Suppl 5):S20-30. PubMed ID: 21813733
[TBL] [Abstract][Full Text] [Related]
17. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
Pi-Sunyer FX
Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
[TBL] [Abstract][Full Text] [Related]
18. An overview of incretin clinical trials.
Garber AJ; Spann SJ
J Fam Pract; 2008 Sep; 57(9 Suppl):S10-8. PubMed ID: 18786339
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure-lowering effects of incretin-based diabetes therapies.
Lovshin JA; Zinman B
Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.
Chilton R; Wyatt J; Nandish S; Oliveros R; Lujan M
Am J Med; 2011 Jan; 124(1 Suppl):S35-53. PubMed ID: 21194579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
